Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of celecoxib loading dose of 400mg followed by 200 mg twice a day
(BID) versus oral non-selective NSAIDs in acute pain due to ankle sprain.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.